TY - JOUR T1 - Prediction Model for Severe Community-acquired Pneumonia Development among Patients with Diabetes Mellitus JF - medRxiv DO - 10.1101/2021.02.04.21251184 SP - 2021.02.04.21251184 AU - Ruoming Tan AU - Tingting Pan AU - Yuzhen Qiu AU - Jiahui Wang AU - Xiaoling Qi AU - Erzhen Chen AU - Min Zhou AU - Jialin Liu AU - Hongping Qu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251184.abstract N2 - Introduction Diabetes is an independent risk factor for the development of severe community-acquired pneumonia (CAP) and associated with pneumonia-related hospitalization as well as mortality. Here, we assessed several selected biomarkers to determine their predictive value for progression to severe CAP among diabetic patients.Research design and methods A retrospective cohort study of diabetic patients with CAP was conducted at a tertiary teaching hospital. The prediction model group (N=100) comprised patients registered between January 2015 to December 2016. Multivariate analysis was performed to identify predictive biomarkers from this cohort. The validation group (N=108) comprised the patients between January 2017 to February 2019. Predictive performance was assessed in the validation group.Results A total of 208 diabetic inpatients with CAP were recruited. Further multivariate analysis showed that C-reactive protein (CRP), absolute lymphocyte count (ALC), immunoglobulin (IgM), and HbA1C at admission were independently associated with progression to severe CAP in diabetic patients during hospitalization. The prediction model =0.0179555*CRP+1.975918* HbA1C-2.879364* ALC −0.026255* IgM − 8.220555. The area under ROC (AUROC) curve in the validation group was 0.851 (0.781–0.921) with statistical significance (P<.05).Conclusions In diabetic patients with CAP, a combination of CRP, ALC, IgM, and HbA1C at admission could be used to predict the progression to severe CAP.Significance of this studyWhat is already known about this subject?What is already known about this subject?Diabetes is an independent risk factor for the development of severe community-acquired pneumonia (CAP) and associated with pneumonia-related hospitalization as well as mortality.It is essential to identify these patients early and prevent them from progressing to SCAP to improve clinical outcomes.What are the new findings?What are the new findings?C-reactive protein (CRP), absolute lymphocyte count (ALC), immunoglobulin (IgM), and HbA1C at admission were independently associated with progression to severe CAP in diabetic patients during hospitalization.The prediction model = 0.0179555*CRP+1.975918* HbA1C-2.879364* ALC −0.026255* IgM − 8.220555.The area under ROC (AUROC) curve in the validation group was 0.851 (0.781–0.921) with statistical significance (P<.05).How might these results change the focus of research or clinical practice?How might these results change the focus of research or clinical practice?In patients with diabetes and CAP, HbA1C, CRP, ALC, IgM at admission, and their combination could be used to predict the progression to severe CAP during hospitalization with good accuracy.Due to the included biomarkers are common, our finding may be performed well in clinical practice and then improve the early management of diabetic patients with CAP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Key R&D Program of China (2017YFC1309700, 2017YFC1309705), National Natural Science Foundation of China (81772040, 81770005, 81801885), Shanghai Sailing Program (18YF1413800), Guangci Excellent Youth Training Program of Ruijin Hospital (GCQN-2019-B14) and Emergency science and technology projects of Shanghai Science and Technology Commission (No. 20411950300/20411950301).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine, China. Informed consent from study patients was not required because of the retrospective design of the cohort study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available. ER -